Study to characterize the steady-state pharmacokinetics of codeine and its metabolites
morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) after oral
administration of Roxane Laboratories' codeine sulfate tablets administered at a dose of 15
mg Q4H x 5 days.
Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions
The objective of this study designed to characterize the pharmacokinetics and comparative
bioavailability of Roxane Laboratories' codeine sulfate tablets after oral administration of
60 mg doses as 1 x 60 mg, 2 x 30 mg and 4 x 15 mg under fasted conditions.
Comparative Bioavailability Study of Codeine Sulfate
The objective of this study was to assess the comparative bioavailability of codeine from
Roxane Laboratories' Codeine Sulfate 30mg tablets to Tylenol® #3 (acetaminophen 300mg with
codeine phosphate 30mg) under fasted conditions
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.